- Revvity recently reported past fourth-quarter 2025 results with adjusted earnings of US$1.70 per share on 5.9% revenue growth, while issuing 2026 guidance that aligned with but did not lift already reduced analyst expectations.
- A contemporaneous Bretton Fund letter criticized Revvity’s use of its Covid testing windfall on overpriced deals and divestitures, highlighting investor unease with management’s capital allocation choices despite the company’s remaining potential.
- We’ll now examine how Revvity’s cautious 2026 outlook and questioned capital allocation decisions may reshape its previously optimistic investment narrative.
AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Revvity Investment Narrative Recap
To own Revvity, you need to believe its mix of life sciences tools, diagnostics, and software can translate into steadier growth and better margins over time. The latest earnings beat and modest 2026 guidance do not appear to materially change the near term catalyst, which is execution on organic growth and margin improvement, nor the key risk, which remains management’s capital allocation discipline after criticism of past deals and divestitures.
The most relevant recent development is Bretton Fund’s decision to exit Revvity after concluding that the Covid testing cash was spent on overpriced acquisitions while the profitable food testing unit was sold. That critique lands directly against the current catalyst of expanding higher margin software and consumables, because it puts extra focus on whether future investments, divestitures, and buybacks will truly support the growth and margin story.
Yet investors should be aware that questions over capital allocation and deal quality could still...
Read the full narrative on Revvity (it's free!)
Revvity's narrative projects $3.3 billion revenue and $599.9 million earnings by 2028. This requires 5.4% yearly revenue growth and about a $321 million earnings increase from $278.7 million today.
Uncover how Revvity's forecasts yield a $114.62 fair value, a 19% upside to its current price.
Exploring Other Perspectives
Before this news, the most cautious analysts were already pricing in slower progress, expecting around US$3.2 billion of revenue and US$411 million of earnings by 2028, so you should recognize how much more pessimistic that view is and consider how fresh concerns about acquisitions and divestitures might push expectations even lower.
Explore 2 other fair value estimates on Revvity - why the stock might be worth just $114.62!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Revvity research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Revvity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revvity's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Find 47 companies with promising cash flow potential yet trading below their fair value.
- We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com